Clin2
NCT07003997Possibly a fitRecruiting

JAK inhibitor for depression with inflammation

Major Depressive Disorder

Treatments studied

Part of Mental health clinical trials.

This trial tests a JAK inhibitor (a type of anti-inflammatory drug) for depression that is linked to inflammation. If you have depression or bipolar depression and a high CRP level (a marker of inflammation), you may be eligible.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
100 people
Ages
25 years to 55 years
Study type
Interventional

Who can take part

  • You are between 25 and 55 years old.
  • You have major depression or bipolar disorder (currently depressed).
  • You have stopped all antidepressants or mood stabilizers for at least 4 weeks (8 weeks for Prozac).
  • You have a CRP blood test result of 3 or higher (a sign of inflammation).
  • You do not have an autoimmune disease, serious infections, blood clots, or heart disease.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07493317Recruiting· Phase 2
Tocilizumab for depression with inflammation

This trial tests a medication called tocilizumab, which targets inflammation, to see if it can improve symptoms of major depression in people with signs of inflammation. You may be eligible if you have depression with a high monocyte count and significant loss of interest or pleasure.

New York, New York
NCT05644301Recruiting· Phase 3
Blood-marker guided add-on treatment for major depression

This study tests whether doctors can choose the best add-on immune-related treatment for people with major depressive disorder by using inflammation blood tests. It’s meant for people whose depression has not improved enough with their current antidepressant.

Duffel, Antwerpen
NCT06699966Not yet recruiting· Phase 4
Anti-inflammatory trial for depression

This study tests whether two anti-inflammatory drugs, celecoxib and minocycline, can help treat depression. You may join if you have moderate to severe depression and are not at high risk for certain medical conditions or drug interactions.

NCT07608796Not yet recruiting· Phase 2
JAK inhibitor for depression in male football players

This study tests a new medication (a JAK inhibitor) that may reduce brain inflammation and improve depression and thinking in male football players. It aims to see if this treatment helps with mood and cognitive function.

Atlanta, Georgia
NCT05849038Recruiting· Phase 2
Treating inflammation to improve depression in HIV

This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).

Atlanta, Georgia
NCT05823532Recruiting· Phase 4
Anti-inflammatory treatment test in people with schizophrenia

This Phase 4 study tests how an anti-inflammatory approach affects people with schizophrenia or schizoaffective disorder who also have signs of body inflammation. It may help by targeting inflammation that could be linked to symptoms for some people.

Atlanta, Georgia

Hear when a new Major Depressive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.